Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANTXRL (Anthrax toxin receptor-like) is a protein predicted to have transmembrane signaling receptor activity and to be localized at the cell surface and plasma membrane[2][4][6][8]. The name is derived from sequence similarity to anthrax toxin receptors (ANTXR1/TEM8 and ANTXR2/CMG2), but there is no published evidence that ANTXRL functions as a receptor for anthrax toxin or is involved in the same biological processes. Functional studies are largely absent, and its physiological or pathological significance remains unknown. Changes in gene copy number have been observed in schizophrenia brain tissue, suggesting possible neural relevance but without mechanistic insight[2]. ANTXRL is not considered an experimentally validated or canonical therapeutic target. Further research is required to clarify its biological role and potential relevance in health or disease.
None. No mechanisms of action are known for drugs targeting this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anthrax toxin receptor-like (ANTXRL).